Brought to you by 
CNS drug reformulator NuPathe completes $46.5mm IPO
20 Aug 2010
Executive Summary
A short three months after filing, NuPathe Inc. (neurology drug reformulations) has completed its initial public offering, netting $46.5mm through the sale of 5mm common shares at $10 each. The company had hoped to get between $14-16 per share.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Transdermal
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CNS drug reformulator NuPathe completes $46.5mm IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice